| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Canadian Journal of Anesthesia, Vol 47, 1207-1215, Copyright © 2000 by Canadian Anesthesiologists' Society
ARTICLES |
RC Gallandat Huet, AW Siemons, D Baus, WT van Rooyen-Butijn, JA Haagenaars, W van Oeveren and F Bepperling
Department of Anesthesiology, University Hospital Groningen, The Netherlands. r.c.g.huet@anest.azg.nl
PURPOSE: To compare the new hydroxyethyl starch HES 130/0.4 (Voluven) and the standard HES 200/0.5 (pentastarch) regarding effectiveness for plasma volume substitution and safety of large volumes in heart surgery. METHODS: Fifty-nine patients scheduled for coronary artery bypass grafting were enrolled in a prospective, randomised, double-blind, parallel-group, multicentre, clinical, phase III study. Hydroxyethyl starch was used as the exclusive artificial colloid for acute normovolemic hemodilution, priming of the heart lung machine, and for intra- and postoperative plasma volume substitution from induction of anesthesia until 16 hr after the end of surgery. Efficacy was evaluated by comparing the amount of colloid infused, hemodynamics, and colloid osmotic pressure (COP). Safety endpoints were blood loss, the use of allogeneic blood products, coagulation variables, and adverse events. RESULTS: Effectiveness, as assessed by the total amount of infused HES volumes within the treatment period, was similar between HES 130/0.4 and HES 200/0.5 (2,550 mL +/- 561 mL vs 2,466 mL +/- 516 mL). Also, no differences were found for the use of other colloids (pasteurised plasma), hemodynamics, and COP In HES 130/0.4 patients, the postoperative increase of von-Willebrand factor (vWF) was higher (P < 0.01), blood loss was lower, and less packed red blood cells were transfused. CONCLUSION: Hydroxyethyl starch 130/0.4 is an effective plasma volume expander in heart surgery and may be used as the sole artificial colloid to cover the perioperative period. We found a reduced influence of HES 130/0.4 on the physiologic postoperative increase of vWF.
This article has been cited by other articles:
 |
|
 |
|
  T. Hitosugi, T. Saito, S. Suzuki, I. Kubota, E. Shoda, T. Shimizu, and Y. Oi Hydroxyethyl Starch: The Effect of Molecular Weight and Degree of Substitution on Intravascular Retention In Vivo Anesth. Analg., September 1, 2007; 105(3): 724 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Boldt, M. Wolf, and A. Mengistu A New Plasma-Adapted Hydroxyethylstarch Preparation: In Vitro Coagulation Studies Using Thrombelastography and Whole Blood Aggregometry Anesth. Analg., February 1, 2007; 104(2): 425 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Yap, D. Young, and V. Pathi Effects of gelatine and medium molecular weight starch as priming fluid in cardiopulmonary bypass--a randomised controlled trial. Perfusion, January 1, 2007; 22(1): 57 - 61. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Fries, T. Haas, A. Klingler, W. Streif, G. Klima, J. Martini, H. Wagner-Berger, and P. Innerhofer Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy--a porcine model Br. J. Anaesth., October 1, 2006; 97(4): 460 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Van der Linden and B. E. Ickx The effects of colloid solutions on hemostasis: [Les effets des solutions colloides sur l'hemostase] Can J Anesth, June 1, 2006; 53(6_suppl): S30 - S39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. J. Gu and P. W. Boonstra Selection of priming solutions for cardiopulmonary bypass in adults MMCTS, January 9, 2006; 2006(0109): 1198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Van der Linden, S. G. De Hert, D. Deraedt, S. Cromheecke, K. De Decker, R. D. Paep, I. Rodrigus, A. Daper, and A. Trenchant Hydroxyethyl Starch 130/0.4 Versus Modified Fluid Gelatin for Volume Expansion in Cardiac Surgery Patients: The Effects on Perioperative Bleeding and Transfusion Needs Anesth. Analg., September 1, 2005; 101(3): 629 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Neff, L. Fischler, M. Mark, R. Stocker, and W. H. Reinhart The Influence of Two Different Hydroxyethyl Starch Solutions (6% HES 130/0.4 and 200/0.5) on Blood Viscosity Anesth. Analg., June 1, 2005; 100(6): 1773 - 1780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Evidence-based Colloid Use in the Critically Ill: American Thoracic Society Consensus Statement Am. J. Respir. Crit. Care Med., December 1, 2004; 170(11): 1247 - 1259. [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Morariu, Y. J. Gu, R. C.G. G. Huet, W. A. Siemons, G. Rakhorst, and W. v. Oeveren Red blood cell aggregation during cardiopulmonary bypass: a pathogenic cofactor in endothelial cell activation? Eur. J. Cardiothorac. Surg., November 1, 2004; 26(5): 939 - 946. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Shander, T. Rijhwani, D. Moskowitz, and R. Spence Blood and Starch in Cardiac Surgery Chest, June 1, 2004; 125(6): 2369 - 2370. [Full Text] [PDF]
|
|
|
|
|
|
J. Boldt New Light on Intravascular Volume Replacement Regimens: What Did We Learn from the Past Three Years? Anesth. Analg., December 1, 2003; 97(6): 1595 - 1604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Ickx, F. Bepperling, C. Melot, C. Schulman, and P. J. Van der Linden Plasma substitution effects of a new hydroxyethyl starch HES 130/0.4 compared with HES 200/0.5 during and after extended acute normovolaemic haemodilution Br. J. Anaesth., August 1, 2003; 91(2): 196 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Wilkes Reply Ann. Thorac. Surg., May 1, 2003; 75(5): 1683 - 1683. [Full Text] [PDF]
|
|
|
|
|
|
T. A. Neff, M. Doelberg, C. Jungheinrich, A. Sauerland, D. R. Spahn, and R. Stocker Repetitive Large-Dose Infusion of the Novel Hydroxyethyl Starch 130/0.4 in Patients with Severe Head Injury Anesth. Analg., May 1, 2003; 96(5): 1453 - 1459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Standl, M.-A. Burmeister, F. Schroeder, E. Currlin, J. Schulte am Esch, M. Freitag, and J. Schulte am Esch Hydroxyethyl Starch (HES) 130/0.4 Provides Larger and Faster Increases in Tissue Oxygen Tension in Comparison with Prehemodilution Values than HES 70/0.5 or HES 200/0.5 in Volunteers Undergoing Acute Normovolemic Hemodilution Anesth. Analg., April 1, 2003; 96(4): 936 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Boldt, G. Haisch, S. Suttner, B. Kumle, and A. Schellhaass Effects of a new modified, balanced hydroxyethyl starch preparation (Hextend(R)) on measures of coagulation Br. J. Anaesth., November 1, 2002; 89(5): 722 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jungheinrich, R. Scharpf, M. Wargenau, F. Bepperling, and J.-F. Baron The Pharmacokinetics and Tolerability of an Intravenous Infusion of the New Hydroxyethyl Starch 130/0.4 (6%, 500 mL) in Mild-to-Severe Renal Impairment Anesth. Analg., September 1, 2002; 95(3): 544 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Fries, P. Innerhofer, A. Klingler, U. Berresheim, M. Mittermayr, A. Calatzis, and W. Schobersberger The Effect of the Combined Administration of Colloids and Lactated Ringer's Solution on the Coagulation System: An In Vitro Study Using Thrombelastograph(R) Coagulation Analysis (ROTEG(R)) Anesth. Analg., May 1, 2002; 94(5): 1280 - 1287. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
